共 50 条
The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways
被引:5
|作者:
Ye, Yongju
[1
]
Zhou, Weimei
[2
]
Ren, Yuefang
[3
]
Lu, Jiali
[3
]
Chen, Aixue
[4
]
Jin, Ruiying
[5
]
Xuan, Feilan
[6
]
机构:
[1] Lishui Hosp Tradit Chinese Med, Dept Gynaecol, Lishui, Peoples R China
[2] Jiaojiang Maternal & Child Hlth Hosp, Dept Ultrasound, Taizhou, Peoples R China
[3] Huzhou Matern & Child Hlth Care Hosp, Dept Gynecol, Huzhou, Peoples R China
[4] Changxing Peoples Hosp Chongming Dist, Dept Gynecol, Shanghai, Peoples R China
[5] Jiaojiang Maternal & Child Hlth Hosp, Dept Gynaecol, Taizhou, Peoples R China
[6] Zhejiang Chinese Med Univ, Dept Obstet & Gynecol, Hangzhou TCM Hosp, Hangzhou, Peoples R China
关键词:
Polycystic ovary syndrome;
guizhi fuling wan;
rosiglitazone;
PI3K/AKT/NF-kappa B pathway;
Nrf2/HO-1;
pathway;
OXIDATIVE STRESS;
GRANULOSA-CELLS;
PCOS;
INFLAMMATION;
ASSOCIATION;
AUTOPHAGY;
D O I:
10.1080/09513590.2023.2254848
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective: GuizhiFulingWan (GFW) has been reported to be effective against polycystic ovary syndrome (PCOS) by possessing oxidative stress and inflammation which related to PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathway. This study aims to probe the effects and mechanisms of GFW combined with rosiglitazone on PCOS via PI3K/AKT/NF-kappa B and Nrf2/HO-1 pathways. Methods: A rat PCOS model established by dehydroepiandrosterone (DHEA) injection. The experiment was allocated to control, DHEA, GFW, rosiglitazone, GFW + rosiglitazone groups. Treatment for 30 days, we monitored weight and ovarian weight of rats. Fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), lipid metabolism indexes, estrous cycle and sex hormone-, inflammation-, oxidative stress-related factors were examined. Hematoxylin&eosin staining assessed ovarian tissue pathological changes. Western blot determined PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathways-related markers. Results: GFW and rosiglitazone treatment suppressed body weight and ovarian weight in PCOS rats. They also decreased FBG, FINS, HOMA-IR while inhibited total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and enhanced high-density lipoprotein (HDL). They ameliorated estrous cycle, ovarian histological changes and follicular development. They restrained testosterone (T), luteinizing hormone (LH) and accelerated estradiol (E2), progesterone (P), follicle stimulating hormone (FSH). They inhibited glutathione peroxidase (GSH-Px), malondialdehyde (MDA), superoxide dismutase (SOD) in serum while increased GSH-Px, SOD and decrease MDA in ovarian tissues. They reduced C-reactive protein, interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-1 beta levels. GFW and rosiglitazone co-intervention regulated PI3K/AKT/NF-kappa B and Nrf2/HO-1 pathways in PCOS rats. Conclusion: GFW alleviated ovarian dysfunction in PCOS rats, which may be related to the PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathways.
引用
收藏
页数:12
相关论文